Escape from adamantane: scaffold optimization of novel P2X7 antagonists featuring complex polycycles

Publication date

2019-03-06T14:39:43Z

2019-03-06T14:39:43Z

2017-01-16

2019-03-06T14:39:43Z

Abstract

The adamantane scaffold, despite being widely used in medicinal chemistry, is not devoid of problems. In recent years we have developed new polycyclic scaffolds as surrogates of the adamantane group with encouraging results in multiple targets. As an adamantane scaffold is a common structural feature in several P2X7 receptor antagonists, herein we report the synthesis and pharmacological evaluation of multiple replacement options of adamantane that maintain a good activity profile. Molecular modeling studies support the binding of the compounds to a site close to the central pore, rather than to the ATP-binding site and shed light on the structural requirements for novel P2X7 antagonists.

Document Type

Article


Accepted version

Language

English

Publisher

Elsevier Ltd

Related items

Versió postprint del document publicat a: https://doi.org/10.1016/j.bmcl.2017.01.039

Bioorganic & Medicinal Chemistry Letters, 2017, vol. 27, p. 759-763

https://doi.org/10.1016/j.bmcl.2017.01.039

Recommended citation

This citation was generated automatically.

Rights

cc-by-nc-nd (c) Elsevier Ltd, 2017

http://creativecommons.org/licenses/by-nc-nd/3.0/es